To report the final overall survival (OS) analyses from the TOURMALINE-MM3 and MM4 studies evaluating ixazomib maintenance therapy in newly diagnosed multiple myeloma (NDMM), highlighting the implications of these findings in the context of evolving treatment strategies.
Key Findings:
MM3 showed a PFS improvement of 5.2 months with ixazomib vs placebo (median 26.5 vs 21.3 months, p = 0.002; HR = 0.72).
MM4 demonstrated a PFS improvement of 8.0 months with ixazomib vs placebo (median 17.4 vs 9.4 months, p < 0.001; HR = 0.66).
No statistically significant difference in OS was observed in both studies after 64 months (MM3) and 36 months (MM4) of follow-up.
Interpretation:
While ixazomib improved PFS significantly, the lack of OS benefit suggests that OS may not be a reliable endpoint in the evolving treatment landscape for multiple myeloma, indicating a need for further research.
Limitations:
OS analyses did not account for subsequent therapies, which may influence outcomes.
The studies were limited to specific patient populations, potentially affecting generalizability, and may introduce biases in patient selection.
Conclusion:
Ixazomib maintenance therapy improves PFS in NDMM but does not show a significant OS advantage, highlighting the complexity of evaluating treatment efficacy in the context of evolving therapies and the importance of OS as an endpoint.
by Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Gareth J. Morgan, Cong Li, Catriona Byrne, Kaveri Suryanarayan, Richard Labotka, S. Vincent Rajkumar
